Spinal Muscular Atrophy Market Set to Expand Saliently at a Robust CAGR during the Forecast Period 2018-2026


Posted October 15, 2018 by coherent3

Spinal muscular atrophy (SMA) is a rare, genetically inherited neuromuscular condition. The disease causes loss of movement and progressive muscle weakness due to muscle wasting (atrophy).

 
Spinal muscular atrophy (SMA) is a rare, genetically inherited neuromuscular condition. The disease causes loss of movement and progressive muscle weakness due to muscle wasting (atrophy). The disease is divided into four subtypes (1 to 4) on the basis of the age of onset. SMA type 1 (SMA1) is the most severe form and most common genetic cause of death among infants. Various drugs are available in the market to treat the symptoms of the diseases, however, only one drug is approved for the treatment of SMA so far. Muscle relaxants such as tizanidine, baclofen, and the benzodiazepines can reduce spasticity. Excessive saliva can be treated with glycopyolate, amitriptyline, and atropine or by botulinum injections into the salivary glands. Antidepressants can be helpful in treating depression. Botulinum toxin can also be used to treat drooling or jaw spasms

Download PDF Brochure of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/1920

Spinal muscular atrophy (SMA) is a rare, genetically inherited neuromuscular condition. The disease causes loss of movement and progressive muscle weakness due to muscle wasting (atrophy). The disease is divided into four subtypes (1 to 4) on the basis of the age of onset. SMA type 1 (SMA1) is the most severe form and most common genetic cause of death among infants. Various drugs are available in the market to treat the symptoms of the diseases, however, only one drug is approved for the treatment of SMA so far. Muscle relaxants such as tizanidine, baclofen, and the benzodiazepines can reduce spasticity. Excessive saliva can be treated with glycopyolate, amitriptyline, and atropine or by botulinum injections into the salivary glands. Antidepressants can be helpful in treating depression. Botulinum toxin can also be used to treat drooling or jaw spasms

Market Key Players:-
Biogen, Cytokinetics, Inc., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., and Ionis Pharmaceuticals, Inc.

Request Customization:
https://www.coherentmarketinsights.com/insight/request-customization/1920

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: [email protected]
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By coherent
Country Azerbaijan
Categories Fitness , Health
Tags spinal muscular atrophy market growth , spinal muscular atrophy market share , spinal muscular atrophy market trends
Last Updated October 15, 2018